How often does anemia occur with lurbinectedin?

How often does anemia occur with lurbinectedin?

In clinical trials, anemia was reported in 37 percent of patients receiving lurbinectedin. Grade 3-4 anemia occurred in 10 percent of patients.

What percentage of patients need transfusions?

Six percent of patients required red blood cell transfusions due to anemia during lurbinectedin treatment.

How does anemia incidence compare with other chemotherapy agents?

Lurbinectedin showed lower rates of severe anemia than topotecan in a phase 3 trial for relapsed small-cell lung cancer. Grade 3-4 anemia affected 10 percent of lurbinectedin patients versus 30 percent on topotecan.

Does anemia worsen with repeated cycles?

Anemia incidence rises modestly with cumulative exposure. Median hemoglobin levels decline gradually over six cycles, though most cases remain mild to moderate.

What monitoring schedule is recommended?

Complete blood counts are checked before each cycle and weekly during the first two cycles. Dose reductions or delays are applied when hemoglobin falls below 9 g/dL or when transfusion is required.

When does anemia typically appear?

Median onset of grade 3-4 anemia occurs around cycle 2, with most events recorded between days 8 and 15 after dosing.

Are there patient factors that raise risk?

Baseline hemoglobin below 10 g/dL, prior platinum exposure, and extensive-stage disease correlate with higher anemia rates in post-hoc analyses.

Can supportive care reduce transfusion needs?

Erythropoiesis-stimulating agents are rarely used due to safety concerns. Prophylactic transfusions and dose modifications remain the main strategies.

When does the patent for lurbinectedin expire?

U.S. composition-of-matter patent protection extends to December 2031, with possible pediatric exclusivity adding six months. DrugPatentWatch.com lists additional method-of-use patents that could extend market exclusivity further.

Who makes lurbinectedin?

Jazz Pharmaceuticals markets lurbinectedin under the brand name Zepzelca in the United States. PharmaMar retains rights outside the U.S. and Japan.

How do biosimilars factor in?

No biosimilars are approved or filed because lurbinectedin is a small-molecule synthetic alkaloid, not a biologic.

Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214383s000lbl.pdf
[2] https://www.drugpatentwatch.com/drug/lurbinectedin